NCT03873688 is a NA clinical trial of expiratory muscle training in Cystic Fibrosis, sponsored by Cigdem Emirza.

Who is sponsoring NCT03873688?

NCT03873688 is sponsored by Cigdem Emirza.

What drugs are being tested in NCT03873688?

Interventions in NCT03873688: expiratory muscle training.

What condition does NCT03873688 study?

NCT03873688 studies Cystic Fibrosis.

Is NCT03873688 still recruiting?

NCT03873688 is currently completed. Last updated 13 November 2019.

Last reviewed 2019-11-13 · How we verify

NCT03873688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis

Completed NA Last updated 13 November 2019

What this trial tests

NA trial testing expiratory muscle training in Cystic Fibrosis in 28 participants. Completed in 31 October 2019.

Timeline

2 January 2019

Primary endpoint
31 October 2019

31 October 2019

Quick facts

Lead sponsor	Cigdem Emirza
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	28
Start date	2 January 2019
Primary completion	31 October 2019
Estimated completion	31 October 2019
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

expiratory muscle training

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Cigdem Emirza

Who can join

Adults 8 to 18, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by recurrent airway infections, affecting many systems including lung, pancreas and sweat glands. Cough is an important defense mechanism for clearing the secretions that increase in respiratory diseases. There have been studies investigating the effect of expiratory muscle training on disease groups such as chronic obstructive pulmonary disease, multiple sclerosis, parkinson's disease, and the elderly and healthy individuals. Studies that evaluating effects of expiratory muscle training in cystic fibrosis are limited in the literature. The aim of this study was to evaluate the effect of cough strength in children and adolescents with CF and the effect of expiratory muscle training program on cough strength, exercise capacity, respiratory muscle strength and quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effect of respiratory muscle training on children and adolescents with cystic fibrosis: a systematic review and meta-analysis.
Cai W, Li M, Xu Y, Li M, et al · · 2024 · cited 5× · PMID 38622583 · DOI 10.1186/s12887-024-04726-x

Verify or expand the search:

Other trials of expiratory muscle training

Trials testing the same drug.

NCT06759779 — Inspiratory and Expiratory Muscle Training in Adolescent Volleyball Players · NA · recruiting
NCT05290480 — Expiratory Muscle Training Versus Incentive Spirometry After Colorectal Surgery · NA · completed

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03873688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cigdem Emirza
Last refreshed: 13 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03873688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing